Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance

Therapeutic Advances in Respiratory Disease

Volumn 2, Issue 2, 2008, Pages 37-48

  Donohue, J F ^a   Hanania, N A ^b   Sciarappa, K A ^c   Goodwin, E ^c   Grogan, D R ^c   Baumgartner, R A ^c   Hanrahan, J P ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SUNOVION PHARMACEUTICALS INC   (United States)

Author keywords

arformoterol; COPD; exacerbations; long acting 2 agonists; safety; salmeterol; tolerance

Indexed keywords

ARFORMOTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; LONG ACTING DRUG; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG;

ACCIDENTAL INJURY; ADULT; APNEA; ARTICLE; ASTHMA; BRONCHITIS; BRONCHODILATATION; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CRYPTOCOCCAL MENINGITIS; DISABILITY; DISEASE EXACERBATION; DIZZINESS; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPOXIA; INSOMNIA; LUNG CANCER; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METERED DOSE INHALER; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE HYPERTONIA; NEBULIZATION; NERVOUSNESS; OPEN STUDY; PAIN; PARESTHESIA; PNEUMONIA; POTASSIUM BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINITIS; SIDE EFFECT; SPUTUM; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR;

ALBUTEROL; ARRHYTHMIAS, CARDIAC; BRONCHITIS; BRONCHODILATOR AGENTS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NEBULIZERS AND VAPORIZERS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS; TREMOR;

EID: 60949097937     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465808089455     Document Type: Article

References (30)

1. Baumgartner, R.A., Hanania, N.A., Calhoun, W.J., Sahn, S.A., Sciarappa, K. and Hanrahan, J.P. (2007) Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther 29: 261-278.
2. Bestall, J.C., Paul, E.A., Garrod, R., Garnham, R., Jones, P.W. and Wedzicha, J.A. (1999) Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54: 581-586.
3. Burge, P.S., Calverley, P.M., Jones, P.W., Spencer, S., Anderson, J.A. and Maslen, T.K. (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320: 1297-1303.
4. Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A. et al. (2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361: 449-456.
5. Calverley, P.M., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W. et al. (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775-789.
6. Campbell, M., Eliraz, A., Johansson, G., Tornling, G., Nihlen, U., Bengtsson, T. et al. (2005) Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med 99: 1511-1520.
7. Celli, B.R. (2006) Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. Proc Am Thorac Soc 3: 58-65.
8. Celli, B.R. and MacNee, W. (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23: 932-946.
9. Donaldson, G.C., Seemungal, T.A., Bhowmik, A. and Wedzicha, J.A. (2002) Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57: 847-852.
10. Donohue, J.F. (2004) Therapeutic responses in asthma and COPD. Bronchodilators. Chest 126: 125S-137S.
11. Donohue, J.F. (2005) Combination therapy for chronic obstructive pulmonary disease: clinical aspects. Proc Am Thorac Soc 2: 272-281.
12. Donohue, J.F., Menjoge, S. and Kesten, S. (2003) Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 97: 1014-1020.
13. Donohue, J.F., van Noord, J.A., Bateman, E.D., Langley, S.J., Lee, A., Witek Jr, T.J. et al. (2002) A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122: 47-55.
14. FDA (1995) COSTART: coding symbols for thesaurus of adverse reaction terms, pp. 1-540.
15. FDA and Center for Drug Evaluation and Research (1998) Guidance for industry: E9 statistical principles for clinical trials, pp. 1-43.
16. Hanania, N.A., Sharafkhaneh, A., Barber, R. and Dickey, B.F. (2002) Beta-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med 165: 1353-1358.
17. Handley, D.A., Senanayake, C.H., Dutczak, W., Benovic, J.L., Walle, T., Penn, R.B. et al. (2002) Biological actions of formoterol isomers. Pulm Pharmacol Ther 15: 135-145.
18. Hanrahan, J., Hanania, NA, Calhoun, WJ, Sahn, S.A., Sciarappa, K. and Baumgartner, R.A. (2008) Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD 5: 25-34.
19. Nelson, H.S., Weiss, S.T., Bleecker, E.R., Yancey, S.W. and Dorinsky, P.M. (2006) The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129: 15-26.
20. Niewoehner, D.E., Rice, K., Cote, C., Paulson, D., Cooper, A.D., Korducki, L., Cassino, C. and Kesten, S. (2005) Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. Annal Internal Med 143: 317-326.
21. Pauwels, R.A., Buist, A.S., Calverley, P.M., Jenkins, C.R. and Hurd, S.S. (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163: 1256-1276.
22. Rabe, K.F., Hurd, S., Anzueto, A., Barnes, P.J., Buist, S.A., Calverley, P. et al. (2007) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am J Respir Crit Care Med 176: 532-555.
23. Rossi, A., Kristufek, P., Levine, B.E., Thomson, M.H., Till, D., Kottakis, J. et al. (2002) Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 121: 1058-1069.
24. Salpeter, S.R., Buckley, N.S., Ormiston, T.M. and Salpeter, E.E. (2006) Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144: 904-912.
25. Seemungal, T.A., Donaldson, G.C., Paul, E.A., Bestall, J.C., Jeffries, D.J. and Wedzicha, J.A. (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157: 1418-1422.
26. Sin, D.D., McAlister, F.A., Man, S.F. and Anthonisen, N.R. (2003) Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 290: 2301-2312.
27. Sovani, M.P., Whale, C.I. and Tattersfield, A.E. (2004) A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease. Drug Saf 27: 689-715.
28. Spencer, S., Calverley, P.M., Burge, P.S. and Jones, P.W. (2004) Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 23: 698-702.
29. Szafranski, W., Cukier, A., Ramirez, A., Menga, G., Sansores, R., Nahabedian, S. et al. (2003) Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21: 74-81.
30. Zhang, X., Zhu, F., Olszewski, M. and Robinson, N.E. (1998) Effects of enantiomers of b2-agonists on ACH release and smooth muscle contraction in the trachea. Am J Physiol 274: L32-L38.